Literature DB >> 28450112

NEDD8-activating enzyme inhibitor, MLN4924 (Pevonedistat) induces NOXA-dependent apoptosis through up-regulation of ATF-4.

Xiaojun Liu1, Yanan Jiang1, Jianfu Wu1, Wenjuan Zhang1, Yupei Liang1, Lijun Jia2, Jinha Yu3, L S Jeong4, Lihui Li5.   

Abstract

It has been reported that MLN4924 can inhibit cell growth and metastasis in various kinds of cancer. We have reported that MLN4924 is able to inhibit angiogenesis through the induction of cell apoptosis both in vitro and in vivo models. Moreover, Neddylation inhibition using MLN4924 triggered the accumulation of pro-apoptotic protein NOXA in Human umbilical vein endothelial cells (HUVECs). However, the mechanism of MLN4924-induced NOXA up-regulation has not been addressed in HUVECs yet. In this study, we investigated how MLN4924 induced NOXA expression and cellular apoptosis in HUVECs treated with MLN4924 at indicated concentrations. MLN4924-induced apoptosis was evaluated by Annexin V-FITC/PI analysis and expression of genes associated with apoptosis was assessed by Quantitative RT-PCR and western blotting. As a result, MLN4924 triggered NOXA-dependent apoptosis in a dose-dependent manner in HUVECs. Mechanistically, inactivation of Neddylation pathway caused up-regulation of activating transcription factor 4 (ATF-4), a substrate of Cullin-Ring E3 ubiquitin ligases (CRL). NOXA was subsequently transactivated by ATF-4 and further induced apoptosis. More importantly, knockdown of ATF-4 by siRNA significantly decreased NOXA expression and apoptotic induction in HUVECs. In summary, our study reveals a new mechanism underlying MLN4924-induced NOXA accumulation in HUVECs, which may help extend further study of MLN4924 for angiogenesis inhibition treatment.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ATF-4; Apoptosis; HUVECs; MLN4924; Neddylation

Mesh:

Substances:

Year:  2017        PMID: 28450112     DOI: 10.1016/j.bbrc.2017.04.122

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer.

Authors:  Daniel B Longley; Victoria Coyle; Jennifer Ferris; Margarita Espona-Fiedler; Claudia Hamilton; Caitriona Holohan; Nyree Crawford; Alex J McIntyre; Jamie Z Roberts; Mark Wappett; Simon S McDade
Journal:  Cell Death Discov       Date:  2020-07-21

Review 2.  Protein neddylation and its alterations in human cancers for targeted therapy.

Authors:  Lisha Zhou; Wenjuan Zhang; Yi Sun; Lijun Jia
Journal:  Cell Signal       Date:  2018-01-10       Impact factor: 4.315

3.  Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer.

Authors:  Daniel B Longley; Victoria Coyle; Jennifer Ferris; Margarita Espona-Fiedler; Claudia Hamilton; Caitriona Holohan; Nyree Crawford; Alex J McIntyre; Jamie Z Roberts; Mark Wappett; Simon S McDade
Journal:  Cell Death Discov       Date:  2020-07-21

Review 4.  Neddylation: a novel modulator of the tumor microenvironment.

Authors:  Lisha Zhou; Yanyu Jiang; Qin Luo; Lihui Li; Lijun Jia
Journal:  Mol Cancer       Date:  2019-04-03       Impact factor: 27.401

Review 5.  Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.

Authors:  Daniel Arthur Corpuz Fisher; Jared Scott Fowles; Amy Zhou; Stephen Tracy Oh
Journal:  Front Immunol       Date:  2021-06-01       Impact factor: 8.786

Review 6.  Neddylation: A Versatile Pathway Takes on Chronic Liver Diseases.

Authors:  Jiping Yao; Xue Liang; Yanning Liu; Min Zheng
Journal:  Front Med (Lausanne)       Date:  2020-10-19

7.  Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia.

Authors:  Dan Cojocari; Brianna N Smith; Julie J Purkal; Maria P Arrate; Jason D Huska; Yu Xiao; Agnieszka Gorska; Leah J Hogdal; Haley E Ramsey; Erwin R Boghaert; Darren C Phillips; Michael R Savona
Journal:  Haematologica       Date:  2022-04-01       Impact factor: 9.941

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.